首页> 外文期刊>Bone marrow transplantation >Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows
【24h】

Allogeneic transplantation of peripheral blood stem cell grafts results in a massive decrease of primitive hematopoietic progenitor frequencies in reconstituted bone marrows

机译:外周血干细胞移植物的同种异体移植导致重构骨髓原始造血祖频率的大规模降低

获取原文
获取原文并翻译 | 示例
       

摘要

The success of allogeneic hematopoietic stem cell transplantation (alloSCT) is indicated by the reconstitution of the peripheral blood system of patients after alloSCT and the engraftment of hematopoietic stem and progenitor cells (HSPCs) into their bone marrow (BM). The number of CD34(+) cells is commonly used as surrogate for the content of hematopoietic stem cells in the grafts. During the last decade, several antigens (including CD133, CD45RA, CD38, and CD10) were identified allowing discrimination of different HSPC subpopulations within the human CD34(+) cell compartment. Although such studies increased our understanding of early human hematopoiesis tremendously, hardly any study dissected the CD34(+) compartment in the alloSCT setting. Consequently, we comprehensively analyzed the CD34(+) compartment in G-CSF-stimulated peripheral blood stem cell grafts of allogeneic donors, in BM samples of the respective recipients 4 weeks after alloSCT, and in BM samples of healthy donors. We demonstrate that alloSCT is associated with a dramatic shift from primitive to more mature HSPC types. Upon investigating whether the composition of engrafted CD34(+) cells has any impact on the incidence and severity of graft-versus-host disease, we did not find any correlation. However, more detailed analyses of the CD34(+) compartment may elucidate associations with other transplantation-related complications.
机译:异种造血干细胞移植(Allosct)的成功由患者外周血系统的重建表示,血管生成茎和祖细胞(Hspcs)植入骨髓(BM)。 CD34(+)细胞的数量通常用作移植物中造血干细胞含量的替代物。在过去的十年中,鉴定了几种抗原(包括CD133,CD45RA,CD38和CD10),允许在人CD34(+)细胞室内的不同HSPC亚群的判断。虽然这种研究巨大地提高了对早期人造血的理解,但几乎没有任何研究解释了Allosct环境中的CD34(+)隔室。因此,在Allosct 4周后,在相应的受试者的BM样本中,我们将CD34(+)隔室综合分析了同种异体供体的G-CSF刺激的外周血血液干细胞移植物,并在健康供体的BM样品中。我们证明Allosct与原始转变与更多成熟的HSPC类型相关联。在研究移植的CD34(+)细胞的组成是否对移植物与宿主疾病的发病率和严重程度产生任何影响,我们没有找到任何相关性。然而,CD34(+)隔室的更详细分析可以阐明与其他与移植相关的并发症的关联。

著录项

  • 来源
    《Bone marrow transplantation》 |2020年第1期|共10页
  • 作者单位

    Univ Duisburg Essen Univ Hosp Essen Dept Bone Marrow Transplantat Essen Germany;

    Univ Duisburg Essen Univ Hosp Essen Inst Transfus Med Essen Germany;

    Univ Duisburg Essen Univ Hosp Essen Inst Transfus Med Essen Germany;

    Univ Duisburg Essen Univ Hosp Essen Inst Transfus Med Essen Germany;

    Univ Duisburg Essen Univ Hosp Essen Dept Bone Marrow Transplantat Essen Germany;

    Univ Duisburg Essen Univ Hosp Essen Inst Transfus Med Essen Germany;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 治疗学;
  • 关键词

  • 入库时间 2022-08-19 23:02:52

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号